top of page

The Critical Need for Standardizing Norepinephrine Formulation Reporting in Intensive Care

The Critical Need for Standardizing Norepinephrine Formulation Reporting in Intensive Care

Norepinephrine plays a pivotal role in critical care, especially in the management of septic shock and acute hypotension. Its efficacy, however, is significantly hampered by a lack of uniformity in formulation reporting across different regions of the world. This inconsistency not only poses substantial risks to patient safety but also severely impacts the integrity of scientific research in the field of critical care medicine. Drawing on the findings from a joint task force of the Society of Critical Care Medicine and the European Society of Intensive Care Medicine, this post delves into the urgent call for global standardization in the reporting of norepinephrine formulations [1].

The Essence of Norepinephrine in Critical Care

Norepinephrine is the backbone of vasopressor therapy in critical care settings, recommended as the first-line agent for managing life-threatening hypotension, notably in septic shock scenarios. Despite its widespread acceptance and usage, the reporting of norepinephrine in various formulations—specifically as a base molecule versus its salt forms—creates a wide chasm in dosing accuracy, patient safety, and the comparability of clinical research outcomes.

Which formulation of norepinephrine do you use in your ICU?

  • Norepinephrine hydrochloride

  • Norepinephrine bitartrate

  • Norepinephrine tartrate

The Formulation Conundrum

At the heart of the norepinephrine formulation issue is a complex web of chemical compositions. Norepinephrine is available in several salt formulations for clinical use, each with distinct molecular weights and consequently, different dosing equivalences to the base molecule. This variance is not just a trivial matter of nomenclature but has profound implications for dosing strategies and patient outcomes.

Consider norepinephrine bitartrate and norepinephrine base. If a patient is prescribed 1 mg of norepinephrine, the actual amount of the active drug they receive can vary significantly depending on the formulation. Norepinephrine bitartrate, due to the additional molecular weight of the bitartrate component, means that a dose marked as 1 mg of norepinephrine bitartrate contains only about 0.55 mg of norepinephrine base. This discrepancy can lead to underdosing if the clinician is unaware of the difference, potentially jeopardizing patient outcomes.

Implications of using different norepinephrine
Implications of using different norepinephrine (NE) formulations leading to inappropriately delayed weaning from venoarterial extracorporeal membrane oxygenation (top) and premature addition of adjunctive therapy (bottom).Critical Care Medicine52(4):521-530, April 2024.

Bridging the Gap in Clinical and Research Practices

The variance in norepinephrine reporting significantly undermines the reliability of clinical management strategies and the integrity of research within the critical care domain. It affects critical care metrics such as severity assessments, trial enrollment criteria, and the interpretability of research data—essentially compromising patient care and the advancement of knowledge in critical care medicine.

A Unified Call to Action

The joint task force underscores the necessity for immediate, coordinated efforts to adopt a standardized reporting mechanism for norepinephrine formulations worldwide. This call for action is directed at hospital organizations, clinical practices, researchers, and pharmaceutical manufacturers alike, aiming to establish norepinephrine base formulation reporting as the universal language for dosing and documentation in both clinical and research settings.

The Path Forward

Standardizing the way norepinephrine formulations are reported is more than an administrative adjustment; it's a crucial step toward enhancing patient safety, ensuring the efficacy of clinical practices, and preserving the integrity of critical care research. By aligning on a global scale, the critical care community can pave the way for more reliable treatment strategies, clearer research outcomes, and ultimately, better patient care outcomes in the intensive care unit.

In conclusion, the variability in norepinephrine formulation reporting is a significant challenge that the critical care medicine community faces today. The joint task force's position paper is not just a wake-up call but a roadmap towards harmonization and improved patient care. As we move forward, embracing this change will be pivotal in enhancing the quality of care and research outcomes in critical care settings worldwide.


  1. Wieruszewski, Patrick M. PharmD, BCCCP1,2; Leone, Marc MD, PhD3; Kaas-Hansen, Benjamin Skov MD, MSc, PhD4; Dugar, Siddharth MD, FCCP, FCCM, FASE5,6; Legrand, Matthieu MD, PhD7; McKenzie, Cathrine A. BPharm, PhD8; Bissell Turpin, Brittany D. BCCCP, PharmD, PhD, FCCM9,10; Messina, Antonio MD, PhD11,12; Nasa, Prashant MD, EDIC13; Schorr, Christa A. DNP, MSN, RN, FCCM14,15; De Waele, Jan J. MD, PhD16,17; Khanna, Ashish K. MD, MS, FCCP, FASA, FCCM18,19. Position Paper on the Reporting of Norepinephrine Formulations in Critical Care from the Society of Critical Care Medicine and European Society of Intensive Care Medicine Joint Task Force. Critical Care Medicine 52(4):p 521-530, April 2024. | DOI: 10.1097/CCM.0000000000006176

325 views0 comments


bottom of page